<DOC>
	<DOCNO>NCT00381394</DOCNO>
	<brief_summary>Sitamaquine 8-aminoquinoline develop oral treatment visceral leishmaniasis ( VL ) . Pre-clinical subsequent clinical investigation demonstrate oral efficacy Leishmania donovani . The purpose study characterise pharmacokinetic profile sitamaquine , administer orally , determine pharmacokinetic profile affect administration food . The study also design characterise safety tolerability sitamaquine compare amphotericin B , particularly reference renal , hepatic cardiac adverse event , prior initiation phase III study . Finally study investigate efficacy 21 day treatment course . Previous study use 28 day dose , parasitological evidence one study suggest short course may effective .</brief_summary>
	<brief_title>A Study Evaluating Sitamaquine Compared With Amphotericin B In The Treatment Of Visceral Leishmaniasis .</brief_title>
	<detailed_description />
	<mesh_term>Leishmaniasis</mesh_term>
	<mesh_term>Leishmaniasis , Visceral</mesh_term>
	<mesh_term>Amphotericin B</mesh_term>
	<mesh_term>Liposomal amphotericin B</mesh_term>
	<criteria>Inclusion criterion : Clinical diagnosis visceral leishmaniasis ; symptom sign compatible VL diagnosis confirm visualisation amastigotes splenic aspirate bone marrow . Written inform consent witness oral consent . Willing comply study visit procedure . For female subject , negative urine pregnancy test screen dose subject agrees use establish method birth control ( include abstinence ) . Exclusion criterion : Past history renal disease impair renal function screen . History significant hepatic biliary disease , follow abnormal laboratory value screen ; hepatic dysfunction ( AST ALT 2.5 time upper limit normal ) . Subjects follow abnormal laboratory value ; haemoglobin 6.5 g/dl , neutrophils &lt; 750/ mm3 , platelet &lt; 50,000 / mm3 , clinically relevant abnormality identify screen examination clinical laboratory would preclude subject 's safe participation study . History cardiac disease , arrhythmia , conduction abnormality clinically relevant abnormality identify 12lead ECG screening . Subjects suffer concomitant infection , blood disorder serious underlying disease would preclude evaluation subject 's response study medication . Methaemoglobin level &gt; 5 % screening . G6PD deficiency . Positive HIV antibody , hepatitis B surface antigen hepatitis C antibody screen . Pregnant nursing woman ; woman childbearing potential unwilling unable use appropriate form contraception , prior study medication administration 2 week follow last dose investigational product . Any contraindication splenic aspirate ( bone marrow aspirate ) , include limited PT prolong &gt; 3 second longer control platelet &lt; 50,000 / mm3 . Subjects know hypersensitivity reaction 8aminoquinolines ( e.g . primaquine ) investigational product excipients . Treatment establish antileishmanial chemotherapeutic agent within 30 day 5 halflives ( whichever longer ) precede first dose study medication . Treatment investigational drug within 30 day 5 halflives ( whichever longer ) precede first dose study medication .</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>February 2011</verification_date>
	<keyword>amphotericin B</keyword>
	<keyword>safety</keyword>
	<keyword>tolerability pharmacokinetics oral sitamaquine</keyword>
	<keyword>Visceral leishmaniasis</keyword>
</DOC>